Follow-up study for people with high EBV virus levels
Part of Blood & lymphatic, Infections clinical trials.
This study tracks health outcomes over time in people who have a high level of the EBV virus in their blood. It may help researchers understand what happens in chronic (long-lasting) EBV infection and which outcomes to watch for.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood test showing high EBV levels (more than 1×10³ copies per milliliter)
- You can take part in follow-up interviews by phone or in person
- You do not have a known immune system problem (immunodeficiency)
- You are not taking, and do not plan to take, medicines that suppress the immune system
- You do not have blood cancer or a confirmed blood disorder (hematopathy)
- You are able to understand the study and participate willingly
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether two products (2LEBV® and 2LXFS®) can improve ongoing fatigue in people who have evidence of an Epstein-Barr virus (EBV) infection. It aims to see if treatment helps reduce multiple related symptoms over follow-up.
This study looks at how the immune system’s antibodies behave after a first-time EBV infection, including whether they mistakenly react with the body’s own tissues. You might be offered a chance to help doctors understand why some people get longer or more intense symptoms from infectious mononucleosis.
This Phase 1 study tests an immune-cell therapy made to recognize EBV (a common virus) in people whose lymphoma contains EBV. It may help control EBV-driven cancers, especially when standard treatment isn’t working or can’t be used.
This trial tests a new immune therapy for people with Epstein-Barr virus (EBV)-related lymphoproliferative diseases, including chronic active EBV and conditions that can occur after an organ or stem cell transplant. It aims to see if the therapy can safely control the disease.
This study collects medical information and blood samples from people with Epstein-Barr virus-positive T/NK-cell lymphoproliferative diseases to better understand how these conditions progress and respond to treatment. It includes a retrospective part (looking back at medical records) and a prospective part (following people forward in time).
This trial tests whether special immune cells (called EBV-TCR-T cells) can help clear the Epstein-Barr virus in people who still have high virus levels after a stem cell transplant. It's an experimental therapy for those whose virus hasn't responded to standard care.
Hear when a new EBV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.